FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment Phase II study extension shows 68-73% of patients with multiple ...

A new study indicates that the drug FTY720 prevents disease in a mouse model of two leukemias -- blast crisis chronic myeloid leukemia and acute lymphocytic leukemia -- caused by the cancer protein ...

‡ Relapse rate over 2 years. im.: Intramuscular; iv.: Intravenous; NA: Not available in pivotal clinical trials; p.o.: By mouth; sc.: Subcutaneous. Data taken from ...

Alexandria, VA, USA – A study aiming to deliver Fingolimod (FTY720) loaded polymer scaffolds to enhance oral wound healing by modulating pro-regenerative immune cell migration associated with improved ...

Estrogen receptor-α (ERα)-negative breast cancer is clinically aggressive and does not respond to conventional hormonal therapies. Strategies that lead to re-expression of ERα could sensitize ...

FREEDOMS study shows FTY720 reduced relapse rates by 54-60% compared to placebo, and disability progression by 30-32%[1] Results build on Phase III TRANSFORMS one-year study showing FTY720 reduced ...

Impact of AKT inhibitor MK-2206 on erlotinib resistance in non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract does not include a ...

Data presented at the American Academy of Neurology show annual relapse rates reduced by 62% in newly treated patients Relapse rates reduced by 44% in previously treated patients New extension data ...

CHICAGO – A drug that can be taken orally reduces the number of attacks people with multiple sclerosis (MS) have, according to research that will be presented at the American Academy of Neurology 60th ...

ZURICH (Reuters) - Novartis AG's once-daily FTY720 pill reduced the number of attacks suffered by patients with multiple sclerosis (MS) after three years, according to data presented on Tuesday.